Keywords: مهار کننده آکت; AKT inhibitor; autoimmune adverse effects; autoimmune dermopathies; B-RAF; dabrafenib; dermatitis; dual inhibitor; dysgeusia; everolimus; hair loss; hedgehog signaling pathway; immunotherapy; immune-related toxicities; ipilimumab; keratoacanthoma; keratos
مقالات ISI مهار کننده آکت (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Discovery of chiral dihydropyridopyrimidinones as potent, selective and orally bioavailable inhibitors of AKT
Keywords: مهار کننده آکت; AKT inhibitor; GSK3β; ATP competitive; Orally bioavailable;
Protection of the myocardium against ischemia/reperfusion injury by angiotensin-(1-9) through an AT2R and Akt-dependent mechanism
Keywords: مهار کننده آکت; +dP/dt; maximum derivative of left ventricular pressure; ACE; angiotensin-converting enzyme; ACE2; angiotensin-converting enzyme 2; Akti; Akt inhibitor; AT2R; angiotensin type 2 receptor; CVD; cardiovascular diseases, EC50, effective concentration 50, I/R
Recent progress towards clinically relevant ATP-competitive Akt inhibitors
Keywords: مهار کننده آکت; Akt inhibitor; Kinase inhibitor; PI3K/Akt/mTOR pathway; Clinical candidate;
The inhibition of Akt-Pdpk1 interaction efficiently suppresses the growth of murine primary liver tumor cells
Keywords: مهار کننده آکت; Protein kinase B; PDPK1; AKT inhibitor; Cancer treatment; Cell signaling;
Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate Cancer in Preclinical Models
Keywords: مهار کننده آکت; Akt inhibitor; Apoptosis; Enzalutamide; Prostate cancer;
High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models
Keywords: مهار کننده آکت; Prostate cancer; Targeted therapy; PI3K inhibitor; AKT inhibitor; Androgen receptor;
Inhibition of hedgehog signaling by GANT58 induces apoptosis and shows synergistic antitumor activity with AKT inhibitor in acute T cell leukemia cells
Keywords: مهار کننده آکت; T-ALL; GLI1; GANT58; AKT inhibitor; Apoptosis; Hh; hedgehog; T-ALL; acute T cell leukemia; SMO; Smoothened; GLI1; GLI family zinc finger 1; SHH; Sonic hedgehog; DHH; Desert hedgehog; IHH; Indian hedgehog; PTCH1; Patched 1; PI3K; phosphatidylinositol 3-kin
AKT inhibition synergistically enhances growth-inhibitory effects of gefitinib and increases apoptosis in non-small cell lung cancer cell lines
Keywords: مهار کننده آکت; NSCLC; EGFR; AKT; S6; Gefitinib; Akt inhibitor; Synergism;
Suppression of Antifolate Resistance by Targeting the Myosin Va Trafficking Pathway in Melanoma
Keywords: مهار کننده آکت; ChIP; chromatin immunoprecipitation; FLIM; fluorescence lifetime imaging microscopy; IAKT; Akt inhibitor; MTX; methotrexate; MyoVa; myosin Va; PP2A; protein phosphatase 2A; UCN-01; 7-hydroxystaurosporine;
Pyrazolopyrimidines as dual Akt/p70S6K inhibitors
Keywords: مهار کننده آکت; p70S6K inhibitor; Akt inhibitor; Pyrazolopyrimidine; PI3K pathway; Cancer
Targeting the AKT/GSK3β/Cyclin D1/Cdk4 Survival Signaling Pathway for Eradication of Tumor Radioresistance Acquired by Fractionated Radiotherapy
Keywords: مهار کننده آکت; Radioresistance; Fractionated radiation; AKT inhibitor; AKT; Cyclin D1;
A 4-aminoquinoline derivative that markedly sensitizes tumor cell killing by Akt inhibitors with a minimum cytotoxicity to non-cancer cells
Keywords: مهار کننده آکت; Chloroquine analog; Akt inhibitor; Breast cancer; Chemotherapeutics; 184B5;
Akt inhibitor enhances apoptotic effect of carboplatin on human epithelial ovarian carcinoma cell lines
Keywords: مهار کننده آکت; Carboplatin; Akt inhibitor; Epithelial ovarian carcinoma cell; Apoptosis-related protein; Cell death
Glucagon-like peptide-1 (GLP-1) protects against methylglyoxal-induced PC12 cell apoptosis through the PI3K/Akt/mTOR/GCLc/redox signaling pathway
Keywords: مهار کننده آکت; GLP-1; apoptosis; PC12 cells; diabetic encephalopathy; methylglyoxal; AD; Alzheimer's disease; AGE; advanced glycation endproduct; Akt-I; Akt inhibitor; BBB; blood-brain barrier; cAMP; adenosine 3â²,5â²-cyclic monophosphorothioate; DAPI; 4â²,6-diamid
Oncogenic mutation of PIK3CA in small cell lung carcinoma: A potential therapeutic target pathway for chemotherapy-resistant lung cancer
Keywords: مهار کننده آکت; Small cell lung cancer; PIK3CA; Mutation; AKT inhibitor; Cisplatin
Rapid assembly of diverse and potent allosteric Akt inhibitors
Keywords: مهار کننده آکت; Akt inhibitor; Allosteric; Rapid assembly; Cancer; Kinase
Anticancer therapeutics: A surge of new developments increasingly target tumor and stroma
Keywords: مهار کننده آکت; Tumor; Stroma; Drug resistance; Thrombospondins; Galectins; Hypoxia; Angiogenesis; Lysyl oxidases; Akt inhibitor; DLL4; Taxanes; Nodal; TRAIL; Sunitinib; Sorafenib; cMET inhibitor
Design and synthesis of pyridine–pyrazolopyridine-based inhibitors of protein kinase B/Akt
Keywords: مهار کننده آکت; Protein kinase B; Akt inhibitor; Serine/threonine kinase; Pyrazolopyridine
Isoquinoline–pyridine-based protein kinase B/Akt antagonists: SAR and in vivo antitumor activity
Keywords: مهار کننده آکت; Akt inhibitor; Protein kinase B; PKB; GSK3; FL5.12-Akt; Anticancer
Discovery and SAR of oxindole–pyridine-based protein kinase B/Akt inhibitors for treating cancers
Keywords: مهار کننده آکت; Akt inhibitor; Protein kinase B; PKB; GSK3; FL5.12-Akt; Anticancer